Hagen Kennecke, MD, MHA, FRCPC: Benefit of Cabozantinib in Patients with Advanced Neuroendocrine Tumors

January 13, 2026

Hagen Kennecke, a medical oncologist and professor of medicine at Oregon Health Sciences University, discusses the efficacy of cabozantinib in patients with advanced neuroendocrine tumors, specifically in relation to progression-free survival.

MORE EXPERT PERSPECTIVES IN NET:

Hagen Kennecke, MD, MHA, FRCPC: Cabozantinib as a Treatment Option Following Progression in NET

Learn how cabozantinib may help treat neuroendocrine tumors after progression, with expert insights on its role as a next-line option when prior therapies stop working.

Hagen Kennecke, MD, MHA, FRCPC: Benefit of Cabozantinib in Patients with Advanced Neuroendocrine Tumors

MORE EXPERT PERSPECTIVES IN NET:

Hagen Kennecke, MD, MHA, FRCPC: Cabozantinib as a Treatment Option Following Progression in NET

Learn how cabozantinib may help treat neuroendocrine tumors after progression, with expert insights on its role as a next-line option when prior therapies stop working.

Neena Vijayvergia, MD: Importance of Patient Education for Treating Neuroendocrine Tumors

Learn why patient education and strong communication with your care team are important when treating neuroendocrine tumors.